Suppression of testosterone production using abiraterone acetate (AA) with or without androgen deprivation therapy (ADT) in metastatic castration resistant prostate cancer (mCRPC).

被引：3
|
作者：
Jha, Gautam Gopalji
Jeff, Engle
机构：
[1] Univ Minnesota, Minneapolis, MN USA
[2] Fairview Pharm Serv, Minneapolis, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5049
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
    Angelergues, Antoine
    Maillet, Denis
    Flechon, Aude
    Ozguroglu, Mustafa
    Mercier, Florence
    Guillot, Aline
    Le Moulec, Sylvestre
    Gravis, Gwenaelle
    Beuzeboc, Philippe
    Massard, Christophe
    Rouge, Thibault De La Motte
    Delanoy, Nicolas
    Elaidi, Reza-Thierry
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [32] First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel
    Li, Jian-Ri
    Wang, Shian-Shiang
    Yang, Cheng-Kuang
    Chen, Chuan-Su
    Ho, Hao-Chung
    Chiu, Kun-Yuan
    Hung, Chi-Feng
    Cheng, Chen-Li
    Yang, Chi-Rei
    Chen, Cheng-Che
    Wang, Shu-Chi
    Lin, Chia-Yen
    Ou, Yen-Chuan
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [33] Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Nanus, David M.
    Posadas, Edwin M.
    Petrylak, Daniel Peter
    Bruce, Justine Yang
    Lim, Emerson A.
    Peng, Weimin
    Maul, Raymond Scott
    Gonzalez, Martha
    Tran, Namphuong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [34] Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Madan, R. A.
    Donahue, R.
    Tsai, Y-T.
    Karzai, F.
    Gandhy, S.
    Bilusic, M.
    Arlen, P.
    Theoret, M.
    Marte, J.
    Cordes, L.
    Couvillon, A.
    Hankin, A.
    Williams, M.
    McMahon, S.
    Figg, W. D.
    Dahut, W.
    Schlom, J.
    Gulley, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1191 - S1191
  • [35] An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx)
    Efstathiou, Eleni
    Deshpande, Hari
    George, Daniel
    Joshua, Anthony M.
    Taplin, Mary-Ellen
    Griffin, Thomas W.
    Londhe, Anil
    Todd, Mary
    Molina, Arturo
    CANCER RESEARCH, 2014, 74 (19)
  • [36] Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate
    Giacinti, Silvana
    Carlini, Paolo
    Roberto, Michela
    Bassanelli, Maria
    Strigari, Lidia
    Pavese, Francesco
    Aschelter, Anna M.
    Felici, Alessandra
    Valeriani, Maurizio
    Cognetti, Francesco
    Marchetti, Paolo
    ANTI-CANCER DRUGS, 2017, 28 (01) : 110 - 115
  • [37] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [38] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    Drugs, 2012, 72 (2) : 192 - 192
  • [39] Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302
    Smith, Matthew R.
    Matheny, Shannon
    Saad, Fred
    Rathkopf, Dana E.
    Mulders, Peter F. A.
    De Bono, Johann Sebastian
    Small, Eric Jay
    Shore, Neal D.
    Fizazi, Karim
    Kheoh, Thian San
    Li, Jinhui
    Todd, Mary Beth
    Griffin, Thomas W.
    Yu, Margaret K.
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [40] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64
12345